{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:50:46Z","timestamp":1790142646854,"version":"4.0.1"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Ofatumumab is a humanized monoclonal antibody that targets CD20-positive B cells. It was approved by the FDA in 2020 for the treatment of relapsing multiple sclerosis (RMS) in adult patients, and in 2009 for the treatment of Chronic Lymphocytic Leukemia (CLL). With the escalating clinical application of Ofatumumab, comprehending its safety profile within actual healthcare environments is of considerable importance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study compiled a dataset derived from the FAERS database, which included real-world safety data on Ofatumumab from Q4 2009 to Q2 2024. We applied four distinct methodologies, including ROR, PRR, MGPS, and BCPNN, to perform a disproportionality analysis of adverse events (AEs) associated with Ofatumumab. Furthermore, we utilized the Weibull distribution model to estimate the temporal risk pattern of AEs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The investigation incorporated a total of 24,468 case reports pertaining to AEs associated with Ofatumumab. The commonly observed AEs encompass Fatigue, Headache, Chills, Pyrexia, Pain, Nausea, Nasopharyngitis, Vomiting, Urinary tract infection, and Pneumonia. Additionally, we identified potential AEs not specified on the drug label, such as Asthenia, Hypoesthesia, Dizziness, Malaise, Injection site pain, Paresthesia, and Diarrhea.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This investigation has identified several AEs associated with Ofatumumab and revealed previously unacknowledged potential adverse reaction signals. Healthcare providers can refer to these adverse reaction signals to more comprehensively consider the possible conditions that patients may present with during actual clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1515730","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T05:11:08Z","timestamp":1737609068000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system"],"prefix":"10.3389","volume":"16","author":[{"given":"Yue","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingguang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyou","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.12.025","article-title":"Anti-CD20-mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives","volume":"97","author":"Crickx","year":"2020","journal-title":"Kidney Int"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00843-8","article-title":"Clinical perspectives on the molecular and pharmacological attributes of anti-CD20 therapies for multiple sclerosis","volume":"35","author":"Bar-Or","year":"2021","journal-title":"CNS Drugs"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2009.04.009","article-title":"Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20","volume":"46","author":"Du","year":"2009","journal-title":"Mol Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41590-018-0135-x","article-title":"Reassessing B cell contributions in multiple sclerosis","volume":"19","author":"Li","year":"2018","journal-title":"Nat Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.cellimm.2006.02.005","article-title":"B cells as antigen presenting cells","volume":"238","author":"Rodr\u00edguez-Pinto","year":"2005","journal-title":"Cell Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21939","article-title":"Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS","volume":"67","author":"Bar-Or","year":"2010","journal-title":"Ann Neurol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"310ra166","DOI":"10.1126\/scitranslmed.aab4176","article-title":"Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy","volume":"7","author":"Li","year":"2015","journal-title":"Sci Transl Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2018.01.021","article-title":"Multiple sclerosis: mechanisms and immunotherapy","volume":"97","author":"Baecher-Allan","year":"2018","journal-title":"Neuron"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1004795","article-title":"Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic","volume":"14","author":"De S\u00e8ze","year":"2023","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awp070","article-title":"The relation between inflammation and neurodegeneration in multiple sclerosis brains","volume":"132","author":"Frischer","year":"2009","journal-title":"Brain"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy151","article-title":"The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells","volume":"141","author":"MaChado-Santos","year":"2018","journal-title":"Brain"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm038","article-title":"Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology","volume":"130","author":"Magliozzi","year":"2007","journal-title":"Brain"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005516","article-title":"Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study","volume":"90","author":"Bar-Or","year":"2018","journal-title":"Neurology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00143-6","article-title":"Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study","volume":"16","author":"Van Oers","year":"2015","journal-title":"Lancet Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-052920-040318","article-title":"The immune response in multiple sclerosis","volume":"17","author":"Rodr\u00edguez Mur\u00faa","year":"2022","journal-title":"Annu Rev Pathol"},{"key":"B19","doi-asserted-by":"crossref","DOI":"10.1201\/9781032629940","volume-title":"Signal Analysis in Pharmacovigilance Principles and Processes","author":"Kumar","year":"2024"},{"key":"B20","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/pds.v13:8","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/ane.v146.5","article-title":"Identification of novel signal of clobazam-associated drug reaction with eosinophilia and systemic symptoms syndrome: A disproportionality analysis","volume":"146","author":"Sharma","year":"2022","journal-title":"Acta Neurol Scand"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2174\/1574886318666230228142856","article-title":"Identification of signal of clindamycin associated renal failure acute: A disproportionality analysis","volume":"19","author":"Javed","year":"2024","journal-title":"Curr Drug Saf"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/pds.v10:6","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2546","article-title":"Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children","volume":"95","author":"Rivkees","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2016.1167184","article-title":"Data mining spontaneous adverse drug event reports for safety signals in Singapore - a comparison of three different disproportionality measures","volume":"15","author":"Ang","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"B27","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1146\/annurev.immunol.23.021704.115707","article-title":"Immunology of multiple sclerosis","volume":"23","author":"Sospedra","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1055\/s-0036-1579739","article-title":"Immunology of multiple sclerosis","volume":"36","author":"Sospedra","year":"2016","journal-title":"Semin Neurol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00288-6","article-title":"Differential diagnosis of suspected multiple sclerosis: considerations in people from minority ethnic and racial backgrounds in North America, northern Europe, and Australasia","volume":"23","author":"Amezcua","year":"2024","journal-title":"Lancet Neurol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03166.x","article-title":"Complement activation plays a key role in the side-effects of rituximab treatment","volume":"115","author":"Van Der Kolk","year":"2001","journal-title":"Br J Haematol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.semarthrit.2008.05.002","article-title":"Serum immunoglobulins and risk of infection: how low can you go","volume":"39","author":"Furst","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30019-4","article-title":"Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial","volume":"4","author":"Jones","year":"2017","journal-title":"Lancet Haematol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"120459","DOI":"10.1016\/j.jns.2022.120459","article-title":"Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: A review","volume":"443","author":"Sharma","year":"2022","journal-title":"J Neurol Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211044479","article-title":"Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study","volume":"28","author":"Bar-Or","year":"2022","journal-title":"Mult Scler"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.3390\/jpm12091474","article-title":"B-cell targeted therapies in patients with multiple sclerosis and incidence of headache: A systematic review and meta-analysis","volume":"12","author":"Mavridis","year":"2022","journal-title":"J Pers Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2005.05136.x","article-title":"The association of brainstem lesions with migraine-like headache: an imaging study of multiple sclerosis","volume":"45","author":"Gee","year":"2005","journal-title":"Headache"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2006.01.015","article-title":"Assessment of MRI abnormalities of the brainstem from patients with migraine and multiple sclerosis","volume":"244","author":"Tortorella","year":"2006","journal-title":"J Neurol Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"105400","DOI":"10.1016\/j.msard.2023.105400","article-title":"Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis","volume":"82","author":"Baker","year":"2024","journal-title":"Mult Scler Relat Disord"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1515730\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T05:11:12Z","timestamp":1737609072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1515730\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2025.1515730"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1515730","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"article-number":"1515730"}}